Education
About Us
Working with TipRanks
Follow Us
Pulse Biosciences (PLSE)
NASDAQ:PLSE
Top Page
Pulse Biosciences
(NASDAQ:PLSE)
48Neutral
Pulse Biosciences (PLSE) vs. S&P 500 (SPY)
Market Cap
$1.04B
Dividend YieldN/A
Average Volume (3M)169.87K
Price to Earnings (P/E)―
Beta (1Y)2.28
Revenue GrowthN/A
EPS Growth12.66%
CountryUS
Employees56
SectorHealthcare
Sector Strength77
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.81
Shares Outstanding61,516,678
10 Day Avg. Volume158,373
30 Day Avg. Volume169,874
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-28.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pulse Biosciences Business Overview & Revenue Model
Company DescriptionPulse Biosciences, Inc. is a bioelectric medicine company headquartered in Hayward, California. It operates within the healthcare sector, focusing on innovative biomedical solutions. The company specializes in developing and commercializing its proprietary Nano-Pulse Stimulation (NPS) technology, which is designed to deliver nano-second pulses of electrical energy to target cells in various medical applications. This technology offers potential advancements in treating dermatological conditions and other healthcare needs.
How the Company Makes MoneyPulse Biosciences primarily generates revenue through the development, marketing, and sale of its medical devices that utilize Nano-Pulse Stimulation technology. The company earns income by selling these devices directly to healthcare providers and dermatology clinics. Additionally, Pulse Biosciences may engage in strategic partnerships and collaborations with other medical and healthcare organizations to expand the application of its technology, thereby opening additional revenue streams. The company's revenue model is heavily reliant on its ability to innovate and successfully commercialize its technological advancements within the medical field.
Pulse Biosciences Financial Statement Overview
Summary
Pulse Biosciences continues to face significant financial challenges, characterized by negative net income and reliance on external financing. Despite some improvements, such as reduced debt and increased cash reserves, the company struggles with profitability and operational efficiency.Income Statement
Pulse Biosciences has faced challenges in its income statement, marked by negative net income and EBIT over the periods reviewed. Despite a recent increase in revenue, the company still experiences negative gross and net profit margins. This indicates ongoing struggles with cost management and profitability, common in early-stage or high R&D-focused companies.30
Negative
Balance Sheet
The balance sheet shows a relatively stable equity position, with a notable reduction in debt levels over time. However, the company's ongoing losses have led to periods of negative equity, posing financial stability risks. The current equity ratio appears healthy, but the historical volatility and negative ROE highlight underlying financial challenges.45
Neutral
Cash Flow
Cash flow analysis reveals a consistent pattern of negative operating and free cash flow, indicating reliance on external financing to sustain operations. While there is a positive trend in cash reserves due to financing activities, the inability to generate positive cash flow from operations remains a critical concern for long-term sustainability.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.74M | 0.00 | 700.00K | 1.42M | 0.00 | 0.00 | Gross Profit |
| 604.00K | -1.21M | -11.24M | -550.00K | -665.00K | -666.00K | EBIT |
| -48.53M | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | EBITDA |
| -47.33M | -42.37M | -56.70M | -61.87M | -48.87M | -46.79M | Net Income Common Stockholders |
| -46.13M | -42.21M | -58.95M | -63.16M | -49.74M | -45.99M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 59.58M | 44.37M | 61.14M | 28.61M | 20.48M | 25.40M | Total Assets |
| 70.64M | 59.15M | 77.88M | 54.25M | 41.29M | 41.91M | Total Debt |
| 0.00 | 9.14M | 75.96M | 11.25M | 11.36M | 6.72M | Net Debt |
| -51.10M | -35.22M | 14.82M | -17.36M | -1.11M | -180.00K | Total Liabilities |
| 4.31M | 14.79M | 80.13M | 18.56M | 18.40M | 11.18M | Stockholders Equity |
| 66.33M | 44.36M | -2.25M | 35.69M | 22.89M | 30.74M |
| Cash Flow | Free Cash Flow | ||||
| -34.09M | -33.16M | -47.41M | -54.53M | -35.81M | -34.79M | Operating Cash Flow |
| -33.98M | -33.04M | -47.01M | -54.10M | -35.37M | -34.19M | Investing Cash Flow |
| -115.00K | -121.00K | -401.00K | 7.56M | 10.04M | -10.10M | Financing Cash Flow |
| 62.74M | 16.39M | 79.94M | 62.69M | 30.89M | 82.00K |
Pulse Biosciences Technical Analysis
Negative
16.91
Price Trends
19.17
Negative
18.56
Negative
17.20
Negative
Market Momentum
-0.82
Positive
35.62
Neutral
26.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLSE, the sentiment is Negative. The current price of 16.91 is below the 20-day moving average (MA) of 18.48, below the 50-day MA of 19.17, and below the 200-day MA of 17.20, indicating a bearish trend. The MACD of -0.82 indicates Positive momentum. The RSI at 35.62 is Neutral, neither overbought nor oversold. The STOCH value of 26.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLSE.
Pulse Biosciences Risk Analysis
Pulse Biosciences disclosed 61 risk factors in its most recent earnings report. Pulse Biosciences reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pulse Biosciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $27.62B | 49.62 | 27.63% | ― | 11.34% | 4.24% | |
60 Neutral | $269.40M | ― | -38.45% | ― | 15.29% | 45.45% | |
57 Neutral | $1.18B | ― | -6.14% | ― | -20.89% | 83.44% | |
49 Neutral | $6.86B | 0.03 | -54.79% | 2.48% | 24.62% | -2.84% | |
48 Neutral | $1.04B | ― | -70.28% | ― | ― | 12.66% | |
46 Neutral | $2.44B | ― | -50.74% | ― | -7.03% | -20233.78% | |
35 Underperform | $3.51M | ― | 366.81% | ― | -30.19% | 97.74% |
* Healthcare Sector Average
Performance Comparison
PLSE
Pulse Biosciences
16.91
7.11
72.55%
CERS
Cerus
1.45
-0.41
-22.04%
DXCM
Dexcom
70.69
-64.03
-47.53%
QDEL
QuidelOrtho
36.12
-12.88
-26.29%
BLFS
BioLife Solutions
25.00
8.00
47.06%
TTOO
T2 Biosystems
0.12
-3.81
-96.95%
Pulse Biosciences Earnings Call Summary
Earnings Call Date: Oct 30, 2024 | % Change Since: -4.57% | Next Earnings Date: Mar 27, 2025
Earnings Call Sentiment Positive
Pulse Biosciences showed strong clinical and regulatory progress, particularly with their innovative nano-PFA technology, while facing financial challenges due to increased losses and expenses. The company's financial position has strengthened significantly, providing a solid foundation for future developments.Highlights
First Patients Treated with AF Using Nano-PFA Cardiac Surgery System
Pulse Biosciences treated the first patients with atrial fibrillation (AF) using their nano-PFA cardiac surgery system in Europe, marking a significant milestone in their clinical applications.
FDA Breakthrough Device Designation
The cardiac surgery system received U.S. FDA Breakthrough Device Designation for the treatment of AF, and was enrolled in FDA's TAP program, providing even more accelerated pathways than Breakthrough.
Successful Rights Offering
The company completed their rights offering, raising $60 million in gross proceeds with the potential to raise an additional $66 million through the exercise of warrants.
Clinical Progress with Nano-PFA
Over 50 patients successfully treated with the 360 cardiac catheter, showing promise in efficiency and safety in atrial fibrillation treatments.
Financial Strengthening
As of September 30, 2024, cash and cash equivalents totaled $79 million, significantly up from $44.4 million as of December 31, 2023.
Lowlights
Increased Net Loss
GAAP net loss in the third quarter of 2024 was $12.7 million compared to $10.6 million in the prior year period. Non-GAAP net loss also increased to $9.4 million from $8.5 million.
Increased Costs and Expenses
Total GAAP costs and expenses rose by $2.4 million to $13.7 million, driven primarily by an increase in noncash stock-based compensation expense.
Company Guidance
During the Pulse Biosciences Q3 2024 earnings call, several key metrics and business updates were discussed. The company reported a GAAP net loss of $12.7 million for the quarter, an increase from $10.6 million in the prior year, with non-GAAP net loss at $9.4 million compared to $8.5 million. Total GAAP costs and expenses rose to $13.7 million, driven mainly by increased non-cash stock-based compensation expenses. The company successfully raised $60 million in gross proceeds through a rights offering, with potential for an additional $66 million from warrant exercises. Cash and cash equivalents totaled $79 million as of September 30, 2024, up from $44.4 million at the end of 2023. The call highlighted significant advancements in their nano-PFA technology, including FDA Breakthrough Device Designation for their cardiac surgery system, and the initiation of their first-in-human feasibility studies for new devices.Pulse Biosciences Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Pulse Biosciences Updates Investors on Cardiac Innovations
Neutral
Jan 14, 2025
On January 14, 2025, Pulse Biosciences released an updated investor presentation on their website highlighting recent advancements in their cardiac treatment product line. This update is intended to inform investors and analysts about the progress in their product development programs, potentially impacting company operations and stakeholder decisions.
Executive/Board ChangesBusiness Operations and Strategy
Pulse Biosciences Appoints Paul LaViolette as CEO
Positive
Jan 13, 2025
Pulse Biosciences announced the appointment of Paul A. LaViolette as Chief Executive Officer and President, effective January 9, 2025. Mr. LaViolette, who has extensive experience in the healthcare and medical technology sectors, will also act as the principal executive and financial officer. This appointment comes with an at-will Employment Agreement, including stock options contingent on performance milestones. The announcement signals a strategic move to leverage Mr. LaViolette’s expertise to enhance the company’s positioning in the medical technology industry, particularly in its innovative nano-PFA technology development and market expansion efforts.
Executive/Board Changes
Pulse Biosciences CEO Resigns Amid Leadership Transition
Neutral
Dec 6, 2024
Pulse Biosciences, Inc. announced the resignation of CEO Burke T. Barrett, with no disputes over company policies or practices. The company continues to advance its nano-PFA devices as planned. Barrett receives salary, severance, stock options, and health benefits per his separation agreement. Kevin P. Danahy and Darrin R. Uecker temporarily assume executive roles until a new CEO is appointed.
Other
Pulse Biosciences’ Co-Chairman Plans Major Stock Purchase
Neutral
Nov 26, 2024
Robert W. Duggan, the controlling stockholder and Co-Chairman of Pulse Biosciences, Inc., is considering buying up to 500,000 shares of the company’s common stock by December 2024. This move, approved under the company’s Insider Trading Policy, could potentially influence the market perception and value of Pulse Biosciences’ stock.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.